Andrew Lane, MD
Otolaryngology · Baltimore, MDNPI 1033152079
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,352 of the $34,010 with a category attached, or 65.7%. 9 manufacturers reported payments, led by Sanofi at 41.2% of the total. Reporting peaked in 2021 at $11,586 and has fallen 98.5% since, to $172 in 2025. Among otolaryngology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $919.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$14K
- Regeneron$14K
- Regeneron Healthcare Solutions, Inc.$5K
- Medtronic$421
- Aerin Medical Inc.$262
- Acclarent, Inc$185
- plus $354 from 3 others
Across 19 payments — averaging $1779.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$28K
- Sanofi$5K
- Regeneron$982
What the payments were for
- Consulting fees$22,35266%
- Speaking & faculty fees$9,50028%
- Travel & lodging$7282%
- Food & beverage$1,4224%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $13,996 |
| Regeneron | 12 | $13,985 |
| Regeneron Healthcare Solutions, Inc. | 3 | $4,808 |
| Medtronic | 8 | $421 |
| Aerin Medical Inc. | 2 | $262 |
| Acclarent, Inc | 1 | $185 |
| Neurent Medical Limited | 1 | $139 |
| GSK | 2 | $123 |
| Optinose US, Inc. | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$30,655
- VIVAER STYLUS$262
- RHINAER STYLUS$262
- TruDi Nav Cable$185
- NEUROMARK Device$139
- NEUROMARK Radiofrequency Generator$139
How this compares
$34,010 in reported general payments places this provider in the 95th percentile of 222 otolaryngology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 52 | $210,884 |
| Dupixent SyringeDupilumab | 27 | $106,527 |
| Mometasone Furoate | 14 | $1,499 |
| Ipratropium Bromide | 13 | $792 |
| Fluticasone Propionate | 17 | $311 |
| Mupirocin | 16 | $90 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Baltimore
- Marc DubinBaltimore$350K
- Patrick HaBaltimore$41K
- Jean KimBaltimore$29K
- Nicholas RowanBaltimore$25K
- Rodney TaylorBaltimore$18K
- Kyle HattenBaltimore$12K
- Alexander HillelBaltimore$11K
- Carole FakhryBaltimore$11K
- Lee AkstBaltimore$10K
- Frank LinBaltimore$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.